Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Ketamine Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study

NCT03284307
View directory record Official record
Conditions
Unconsciousness, Consciousness
Interventions
Dexmedetomidine, Ketamine, Propofol, Midazolam
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 40 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 27, 2026, 7:40 AM EDT
Recruiting Phase 3 Interventional

Nebulized Ketamine for the Treatment of Major Depressive Disorder

NCT06752759
View directory record Official record
Conditions
Severe Depression, Moderate Depression, Ketamine, Midazolam, Peripheral Nervous System Agents, Central Nervous System Agents, Neurotransmitter Agents, Physiologic Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptom, Hypnotics and Sedatives, Anti-anxiety Agents, Tranquilizing Agents, Psychotropic Drugs, Anesthetics Agent
Interventions
nebulized ketamine, nebulized midazolam
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years to 88 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 27, 2026, 7:40 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
N-acetylcysteine and ketamine, placebo and ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 27, 2026, 7:40 AM EDT
Not listed Phase 4 Interventional

Ketamine v. Ketorolac for Management of Generalized Tension Type Headache

NCT03221569
View directory record Official record
Conditions
Migraine
Interventions
Intravenous ketamine, Ketorolac, Normal saline
Drug
Lead sponsor
The Brooklyn Hospital Center
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 27, 2026, 7:40 AM EDT
Terminated Phase 4 Interventional Results available

Ketamine for Pain in the Emergency Department

NCT03896230
View directory record Official record
Conditions
Acute Pain
Interventions
Ketamine Injectable Product
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 27, 2026, 7:40 AM EDT
Recruiting Phase 2Phase 3 Interventional

Ketamine & Crisis Response Plan for Suicidal Ideation in the ED

NCT05696691
View directory record Official record
Conditions
Suicide
Interventions
Ketamine Hydrochloride, Crisis Response Plan
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 27, 2026, 7:40 AM EDT
Recruiting Phase 2 Interventional

Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSD

NCT06608277
View directory record Official record
Conditions
Posttraumatic Headache, Posttraumatic Stress Disorder
Interventions
Group A active comparator, Group B active comparator, Group C Experimental, Group D Placebo Comparator
Procedure · Drug · Combination Product + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 27, 2026, 7:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects

NCT01600885
View directory record Official record
Conditions
NMDA Receptor Function
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
3
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 27, 2026, 7:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis

NCT04199468
View directory record Official record
Conditions
Cannabis, Ketamine
Interventions
Active Delta-9-THC, Placebo Delta-9-THC, Active Ketamine, Placebo Ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Sep 27, 2026, 7:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

NCT01892189
View directory record Official record
Conditions
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Interventions
Ketamine, TAK-063, TAK-063 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 27, 2026, 7:40 AM EDT
Completed Phase 2 Interventional Results available

Glutamatergic Modulation of Cocaine-related Deficits

NCT01790490
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Ketamine 0.41 mg/kg, Ketamine 0.71 mg/kg, Lorazepam 2 mg
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 52 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 27, 2026, 7:40 AM EDT
Completed Phase 4 Interventional

Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department

NCT04266288
View directory record Official record
Conditions
Depression, Depression Severe, Depression Acute, Depression and Suicide, Suicidal Ideation
Interventions
Ketamine, Sodium Chloride 0.9%
Drug
Lead sponsor
MercyOne Des Moines Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Sep 27, 2026, 7:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 27, 2026, 7:40 AM EDT
Not listed Phase 1 Interventional

Ketamine for Major Depressive Disorder

NCT03721900
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SHX-001 Active low dose, Placebo, SHX-001 Active High dose
Drug
Lead sponsor
Shenox Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Gaithersburg, Maryland • Boston, Massachusetts • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 27, 2026, 7:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Abuse Potential of Rapastinel in Humans

NCT03799900
View directory record Official record
Conditions
Human Abuse Potential
Interventions
Rapastinel, Ketamine, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 27, 2026, 7:40 AM EDT
Completed Not applicable Interventional Results available

Intranasal Ketamine in Treatment-Resistant Depression

NCT01304147
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, placebo
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 27, 2026, 7:40 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting

NCT02303847
View directory record Official record
Conditions
Chronic Pain
Interventions
Ketamine
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lacey, Washington
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 27, 2026, 7:40 AM EDT
Recruiting No phase listed Observational

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Episode, Major Depression, Major Depressive Disorder, Bipolar Disorder, Bipolar Depression, Obsessive-Compulsive Disorder
Interventions
Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Ketamine, Esketamine, Deep Transcranial Magnetic Stimulation (dTMS)
Device · Drug
Lead sponsor
Mark Niciu
Other
Eligibility
18 Years to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 27, 2026, 7:40 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Ketamine for Acute Suicidal Ideation in the Emergency Department: Randomized Controlled Trial

NCT01892995
View directory record Official record
Conditions
Suicide
Interventions
Ketamine
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Sep 27, 2026, 7:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Low-Dose Ketamine in Children With ADNP Syndrome

NCT04388774
View directory record Official record
Conditions
ADNP Syndrome
Interventions
Ketamine
Drug
Lead sponsor
Alexander Kolevzon
Other
Eligibility
5 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 27, 2026, 7:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 27, 2026, 7:40 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy

NCT03889756
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine infusion, Midazolam infusion
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 27, 2026, 7:40 AM EDT
Withdrawn Phase 2 Interventional

Ketamine and Midazolam Infusions for CRPS: Feasibility Study

NCT05945147
View directory record Official record
Conditions
Complex Regional Pain Syndromes
Interventions
Ketamine, Midazolam, Normal Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2099
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 27, 2026, 7:40 AM EDT
Terminated Phase 3 Interventional Results available

Ketamine Patient-Controlled Analgesia for Acute Pain

NCT02062879
View directory record Official record
Conditions
Acute Pain, Multiple Trauma, Fractures
Interventions
Ketamine, Hydromorphone
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Sep 27, 2026, 7:40 AM EDT